Background: This study provides a direct randomized comparison of a new-generation, non-steroidal aromatase inhibitor, anastrozole (Arimidex®), with a steroidal aromatase inhibitor (formestane) with respect to oestrogen (oestradiol, oestrone, and oestrone sulphate) suppression and tolerability.
Introduction
Breast cancer is the most common cancer affecting women in the US and Europe, and an estimated five million women will be diagnosed with breast cancer in the next decade [1] . The breast tumour stimulating effect of oestrogens is well established and most endocrine therapy is directed against oestrogen-driven tumour growth. Aromatase is the enzyme that catalyses the conversion of androgens (androstenedione and testosterone) to oestrogens (oestrone and oestradiol) by a process known as aromatization. In postmenopausal women, oestrogens are mostly derived from adrenal androgens through this conversion [2, 3] .
Aminoglutethimide was the first inhibitor of aromatase to be widely used for treatment of breast cancer. This aromatase inhibitor, however, lacks selectivity for the aromatase enzyme -as well as inhibiting oestrogen production, it also inhibits the production of aldosterone and cortisol, necessitating co-administration of replacement corticosteroids, usually oral hydrocortisone [4] . This, together with poor tolerability, led to the development of new, less toxic aromatase inhibitors.
Formestane (4-hydroxyandrostenedione) was the first selective, steroidal aromatase inhibitor used in the treatment of advanced breast cancer in postmenopausal women [5] . Due to poor oral bioavailability, however, formestane must be administered by deep intramuscular injection every two weeks, and there are some data to suggest that the clinically recommended dose of 250 mg results in variable suppression of circulating oestrogens, with oestradiol levels beginning to rise before the next intramuscular dose [5] .
Since the introduction of formestane, a number of oral non-steroidal aromatase inhibitors have been developed, and these have been shown to suppress oestrogen levels effectively in postmenopausal women [2] .
Anastrozole (Arimidex®) is a potent, selective, non- Abbreviations: ER = oestrogen receptor, PR = progesterone receptor, ? = unknown, + = positive, -= negative. a n = 30.
steroidal, oral aromatase inhibitor, which is associated with significant reductions in plasma oestrogen levels [6] . Preclinical pharmacological studies have shown that it is a potent inhibitor of placental aromatase, and is selective for the aromatase enzyme complex without affecting the other cytochrome P 450 enzymes involved in the synthesis of adrenal glucocorticoid and mineralocorticoid hormones [7, 8] . In the clinical setting, doses of anastrozole up to 10 mg once daily do not affect cortisol or aldosterone secretion by the adrenal gland, and therefore, do not necessitate co-administration of replacement corticosteroids [9] . A combined analysis of two large randomized trials (identical in design) in postmenopausal women with advanced breast cancer who failed on tamoxifen therapy, has shown that 1 mg anastrozole significantly increases survival time compared with megestrol acetate at a median follow-up of 31 months [10] .
Anastrozole and formestane inhibit aromatase through different mechanisms. Anastrozole interferes with the cytochrome P 450 moiety of the aromatase enzyme system [2] , whereas formestane interacts with the substrate binding site of the aromatase enzyme [11] . Indirect comparisons have indicated that anastrozole may be a more effective inhibitor of the aromatase enzyme and consequently a better suppressant of plasma oestradiol than formestane [6, 12] . However, systematic analytical bias can occur between non-randomized comparisons. This direct, comparative, randomized study was therefore designed to assess the effectiveness of anastrozole and formestane in the suppression of oestradiol, oestrone, and oestrone sulphate and to compare their tolerability.
Patients and methods

Patient selection
Sixty postmenopausal women with advanced breast cancer, failing on tamoxifen but suitable for further endocrine therapy, were enrolled in the study from 18 oncology clinics throughout Europe and South Africa. Postmenopausal status was denned as those patients aged 50 years or over who had not menstruated in the last 12 months, or women of any age with follicle stimulating hormone levels greater than 40 IU/1. Patients had to have some form of measurable or evaluable breast cancer. Measurable disease was defined as the presence of bi-or uni-dimensionally measurable lesions as determined by examination, X-ray, or CAT scan. Any lesions not classified as measurable disease constituted evaluable disease.
Patients were not allowed to receive any systemic treatment for breast cancer in addition to their trial therapy. If any additional systemic therapy for breast cancer was required, trial therapy was withdrawn. Patients were also withdrawn for the following reasons: (1) if they suffered a serious adverse event, (2) the physician considered it would be in the patient's best interest not to continue, (3) an objective progression of disease occurred, or (4) the patient was unwilling or unable to continue treatment.
The trial was designed and monitored to comply with the ethical principles of Good Clinical Practice (GCP) and in accordance with the Declaration of Helsinki. All patients included in the trial had given their written informed consent.
Study design
This was a randomized, open, parallel-group, comparative, multicentre trial. Patients were randomized to receive either anastrozole, 1 mg once daily orally, or formestane, 250 mg once every two weeks, by intramuscular injection. Treatment was continued until progression of disease or withdrawal from the study. Patients were assessed weekly for four weeks, at week 12, and then every three months thereafter until week 48, followed by every 6 months until death or trial end (defined as either two years after the first patient was recruited to the trial, or if progression of the disease was observed), and every 12 months after trial end until death.
Blood samples were taken from each patient for baseline measurements at the entry visit, and thereafter at one, two, three, and four weeks after entry. The samples were taken at approximately the same time of day at each visit.
Efficacy assessments
The primary endpoints were blood oestradiol suppression and tolerability. The secondary endpoints included effects on blood oestrone and oestrone sulphate levels, objective response, and adverse events. Laboratory analyses were conducted 'blind' of the randomized drug treatment. All assays on the same patient were conducted in the same batch. The limit of detection is 3 pmol/1. Abbreviation: LOD -limit of detection.
Primary endpoints
Oestradiol ratio
Serum levels of oestradiol were determined two and four weeks after initial administration of treatment using a method previously reported [11] , These time points were chosen since they coincide with the dosing interval for formestane. Additionally, previously published work on formestane utilised the same sampling times for oestradiol suppression [5] . Due to variability of baseline oestradiol concentrations between individuals, oestradiol values were expressed as the oestradiol ratio, defined as the mean of the levels of oestradiol measured during treatment (two weeks and four weeks after the initial administration of trial treatment) divided by the mean of the level of oestradiol measurements at baseline (at the entry visit), as shown in the equation below. Any oestradiol values that lay below the limit of quantification were substituted by the value assigned as the limit of quantification i.e., 3 pmol/1.
Oestradiol ratio = (week 2 oestradiol + week 4 oestradiol)/2 baseline oestradiol
Statistical analysis
The trial was designed to compare the efficacy of anastrozole with that of formestane using oestradiol ratio as the primary endpoint. To detect a difference in the geometric mean oestradiol suppression of 30% with 80% power at the 5% two-sided level of significance, a population of 54 patients (27 per group) was required. To allow for non-evaluable subjects, 60 patients (30 per group) were recruited. The study was not, however, sufficiently powered to detect statistical differences between treatments for clinical efficacy endpoints. For statistical analysis, the oestradiol ratio and oestradiol concentration at entry were log-transformed and the null hypothesis of no difference between the treatment groups was tested by analysis of co-variance (ANCOVA). Oestrone and oestrone sulphate data were analysed in the same way.
Results
Patient characteristics
Tolerability and safety assessments All adverse events were recorded, irrespective of whether or not they were considered to be related to the trial therapy.
Secondary endpoints
Oestrone and oestrone sulphate levels
Oestrone and oestrone sulphate were assessed using a ratio based on the oestrone and oestrone sulphate levels during treatment (two weeks and four weeks after the initial administration of trial treatment) compared with the level at baseline (at the entry visit) in the same way as described above for oestradiol [13] . Sensitivity limits were 5 pmol/1 and 10 pmol/1 for oestrone and oestrone sulphate, respectively.
Clinical efficacy
All randomized patients were assessed according to UICC (International Union Against Cancer) criteria for tumour response four weeks after the initial administration of trial medication, and at all subsequent visits up to, and including, the visit at which disease progression was observed. Objective response was classified as complete response (CR), partial response (PR), stable disease, or progressive disease for both measurable and non-measurable disease [14] .
The patient characteristics are shown in Table 1 . Patients were enrolled between 27 June and 1 December 1995. The demography was comparable in both groups. Twenty-nine patients treated with anastrozole and 31 patients treated with formestane were eligible for hormonal analyses.
Oestradiol levels
The mean baseline oestradiol concentrations were similar in the two groups (Table 2) . After one week's treatment with anastrozole, the mean serum oestradiol concentrations had fallen by approximately 80% (Table 2) , and this level of suppression was maintained over the next three weeks. As indicated in Table 2 , some patients treated with anastrozole (weeks one and three: three patients; week two: one patient; week four: four patients) had undetectable levels of oestradiol (< 3 pmol/1). After one week of treatment with formestane, serum oestradiol levels fell by about 70%, but at weeks two and four, i.e., immediately before the next two-weekly injection of formestane, there was a trend towards recovery of oestradiol levels ( undetectable oestradiol levels during formestane treatment. Based on the two-and four-week measurements, the mean serum oestradiol levels were reduced by 79% and 58% from baseline with anastrozole and formestane, respectively; this difference was statistically significant (P = 0.0001) ( Table 3) .
Secondary endpoints
Oestrone and oestrone sulphate levels Oestrone and oestrone sulphate baseline levels were similar in both treatment groups. After one week of treatment, the oestrone levels had fallen by 87% in the anastrozole group and by 71% in the formestane group, and the oestrone sulphate levels had fallen by 86% in the anastrozole group and by 76% in the formestane group. The levels of suppression were maintained throughout the four weeks of treatment with anastrozole; however, as seen with the oestradiol levels in the formestane group, there was a trend towards recovery of oestrone and oestrone sulphate levels at weeks two and four ( Figures 2 and 3) . After four weeks of treatment, the oestrone levels were 85% below baseline levels in the anastrozole group and 67% below baseline levels in the formestane group. This difference was statistically significant (P = 0.0043) ( Table 3 ). The oestrone sulphate levels had fallen by 92% in the anastrozole group and by 67% in the formestane group. This difference was also statistically significant (P = 0.0007) ( Table 3 ). The observed differences between the treatments in the oestrone and oestrone sulphate data were similar to the differences seen in the oestradiol data. The results of both analyses were based on subsets of patients who entered the trial. Twenty-three (79%) of the twenty-nine anastrozole patients and twenty-two (71%) of the thirty-one formestane patients were included in the analysis of oestrone ratio, and twelve (41%) of the anastrozole patients and twelve (39%) of the formestane patients were included in the analysis of oestrone sulphate. The small number of eligible patients was due to technical difficulties in deriving the data for oestrone and oestrone sulphate from blood samples.
After one week of treatment, eight patients in the anastrozole group and three patients in the formestane group had levels of oestrone below detectable limits. By week four, six patients in the anastrozole group and two patients in the formestane group had oestrone levels below detectable limits. After one week of treatment, only two patients (in the formestane group) had an oestrone sulphate level that was below the detectable limit. By week 4, undetectable levels of oestrone sulphate were found in the samples of two patients treated with anastrozole.
Clinical efficacy
Five of the twenty-nine (17.2%) women in the anastrozole group and three of the thirty-one (9.7%) women in the formestane group responded to treatment (CR or PR). A further 7 of 29 (24.1%) and 12 of 31 (38.7%) patients in the anastrozole and formestane groups, respectively, showed disease stabilization of ^24 weeks and only one patient from each group showed disease stabilization of <24 weeks. A total of 16 of 29 (55.2%) and 15 of 31 (48.4%) patients in the anastrozole and formestane groups, respectively, showed progression of the disease. The results for objective response (CR/PR) were not statistically significantly different (P = 0.482, 95% CI: 0.47-6.60).
Adverse events
Twenty-four patients experienced an adverse event in the anastrozole group compared with twenty-six in the formestane group. Overall, the incidence of adverse events in the two groups was similar -82.8% and 83.9% of patients treated with anastrozole and formestane, respectively, reported at least one adverse event.
There was a higher incidence of gastrointestinal complaints in patients who received anastrozole, and a higher incidence of headache in patients who received formestane (Table 4) . Formestane was also associated with inflammation and/or pain at the injection site (three reports of each).
Two patients in the anastrozole group and one patient in the formestane group were withdrawn from treatment as a result of adverse events. One patient in the formestane group died from pulmonary oedema and one patient in the anastrozole group died from heart failure; these were deemed not to be related to trial therapy. Due to the small number of patients in the study, the adverse events were not statistically analysed.
Discussion
Whilst ovarian secretion of oestrogens ceases during menopause, the residual oestrogens continue to support breast cancer growth. In this study, anastrozole and (14) 2 (7) 2 (7) 3 (10) 1 (3) NA NA Formestane in = 31) 4(13) 2 (7) 6(19) 1(3) 2 (7) 2 (7) 1 (3) 3 (10) 3 (10) formestane suppressed all three oestrogens considered to be of importance (oestradiol, oestrone, and oestrone sulphate), with anastrozole exerting a greater and more consistent suppression compared with formestane.
There have been numerous studies of the effects of various inhibitors on oestrogen levels, but the analytical variability both between and within laboratories over time makes most comparisons of data between separate studies invalid. This is the first study to provide a direct, randomized, comparison of a new-generation, nonsteroidal aromatase inhibitor (anastrozole) with a steroidal aromatase inhibitor (formestane). Anastrozole produced a greater and more consistent suppression of oestradiol, oestrone, and oestrone sulphate compared with formestane. As might be expected, greater differences between anastrozole and formestane in these parameters were seen at weeks two and four just before formestane was given. However, differences were also seen at weeks one and three, supporting the greater suppression of oestrogens by anastrozole throughout the dosing period. The benefit of doing these assessments at two and four weeks was that it allowed us to compare the results with those of a previous study [5] . The findings in the previous study with respect to the suppression of oestradiol by formestane 250 mg were similar to those seen in the study reported here [5] .
The levels of oestradiol, oestrone, and oestrone sulphate suppression produced by anastrozole in this study were highly comparable with those seen in a previous study [6] in which, at doses of 1 mg and 10 mg once daily, anastrozole led to their suppression by ^83.5%, 86.5%, and 5 93.5%, respectively, irrespective of dose [6] . The same study demonstrated potent inhibition of aromatase by 96.7% and 98.1%, respectively, at the 1 and 10 mg/day doses. The variable suppression of oestradiol by formestane is also similar to that of previously published analyses conducted within the same laboratory [11] .
There is concern with steroidal aromatase inhibitors that cross-reaction may occur in oestrogen radioimmunoassays with the inhibitor or its metabolites. If this had happened in this study, then the apparently greater suppression of plasma oestrogen levels by anastrozole might have been artifactual (anastrozole and its metabolites are very unlikely to cross-react). Two pieces of evidence point strongly against the difference being artifactual. Firstly, a similar pattern of difference between the effects of the two inhibitors was seen for all three oestrogens; it is highly improbable that crossreactions would be similar for each of the three analyses. Secondly, it is clear that plasma levels of all three oestrogens increased just prior to the next injection of formestane. This is the opposite of what would be expected if the levels were artifactually increased by cross-reaction with the drug or its metabolites.
As indicated previously, there were no significant differences between anastrozole and formestane in terms of clinical efficacy; however, the size of the study did not provide the power to detect differences. The clinical significance of the differences in degree and consistency of oestrogen suppression between anastrozole and formestane could not therefore be assessed as this study was powered only to detect statistical differences between treatments with respect to endocrinology and not clinical efficacy. The study does, however, confirm the activity of both agents in advanced breast cancer.
Both anastrozole and formestane were well tolerated, and were associated with a low incidence of treatmentrelated withdrawal. In comparison to the formestane group, the anastrozole group had a higher incidence of gastrointestinal disturbances (nausea and vomiting). An increased incidence of nausea and vomiting has also been reported with the use of other new-generation aromatase inhibitors such as letrozole, fadrozole, and vorozole [15] [16] [17] [18] , suggesting that such events appear to be associated with this class of non-steroidal aromatase inhibitors.
Patients treated with formestane experienced local reactions including injection site pain and injection site inflammation associated with the two-weekly intramuscular injections, as reported previously [5] .
In conclusion, the results of the present study have shown that the suppression seen with anastrozole was more consistent than that with formestane, which showed a trend towards recovery in the levels of oestrogens immediately prior to the time of the next injection. The study also confirmed that orally administrated anastrozole, 1 mg once daily, produced greater suppression of oestradiol levels and reductions in oestrone, and oestrone sulphate levels compared with intramuscular formestane, 250 mg every two weeks. The reductions in oestradiol were statistically greater (P = 0.001) in anastrozole, 1 mg once daily, than on formestane, 250 mg every two weeks. There were no significant differences between anastrozole and formestane with respect to tolerability.
No clinical significance of the differences in oestrogen suppression between anastrozole and formestane could be established from this trial, as it did not have sufficient statistical power. However, the use of a treatment such as anastrozole, which provides a more consistent and significantly greater oestrogen suppression in these women with advanced breast cancer, does seem appropriate.
